Francisco Santamaria, MD
@santamariafcomd.bsky.social
Nephro fellow 🫘 | #NephEdC intern 2024 | IMG 🇲🇽 @FacMedicinaUNAM alumnus | Musician 🎸 | Opinions = Own
Future looks promising...
Phase 3 clinical trials open in 2025 evaluating new treatments for IgA Nephropathy #IgAN from @kdigo.org
#Nephpearls #NephSky
👉🏼 kdigo.org/guidelines/i...
#Nephpearls #NephSky
👉🏼 kdigo.org/guidelines/i...
September 19, 2025 at 3:33 AM
Future looks promising...
Reposted by Francisco Santamaria, MD
➡️ Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Assessing the Efficacy and Safety of Felzartamab for IgA Nephropathy www.kidney-internati...
September 18, 2025 at 1:47 PM
➡️ Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Assessing the Efficacy and Safety of Felzartamab for IgA Nephropathy www.kidney-internati...
Reposted by Francisco Santamaria, MD
In patients post-kidney transplantation, vitamin D insufficiency is associated with higher risk of death-censored graft failure and infection-related mortality. Read more in #ASNKidney360: kidney.pub/KID0942
September 18, 2025 at 4:01 PM
In patients post-kidney transplantation, vitamin D insufficiency is associated with higher risk of death-censored graft failure and infection-related mortality. Read more in #ASNKidney360: kidney.pub/KID0942